drugset
drugset / Trial / NCT02480465

Efficacy and Safety of Lobeglitazone Versus Sitagliptin

NCT02480465 ↗

Phase 4 Unknown 248 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Efficacy and Safety of Lobeglitazone versus Sitagliptin in inadequately controlled by Metformin alone Type 2 Diabetes mellitus Patients with Metabolic syndrome.

Timeline

Start
2015-01
Primary completion
2016-12
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeglitazone Small molecule 0.5 mg Oral
Comparator Sitagliptin Small molecule 100 mg Oral

Indications

type 2 diabetes mellitus